RE: News on its way soon as the regulator requires one14 Apr 2024 11:00
Xv it's definitely new work. Funded by Synairgen and conducted by UKHSA at Porton Down
UKHSA. The Antiviral efficacy of IFN-B1a ( SNG001) against different SARS-CoV-2 variants, in vitro.
Amanda Horton, Sarah A Dudley, Matthew Wand, Daniel Packham, Irebe CanoCeja, Victoria J. Tear, Philip D,Monk J.Mark Sutton, Julia A.Tree ( 6 UKHSA 3 x Synairgen)
"In this study we tested the antiviral efficacy of SNG001, in vitro, against a variety of SARS-CoV-2 variants to provide reassurance that IFN-B1a was effective against the different variants as they emerged.